NEW YORK (GenomeWeb) – The US Food and Drug Administration has accepted Myriad Genetics' supplementary premarket approval application for BRACAnalysis CDx as a test that may be used to identify metastatic breast cancer patients who are most likely to respond to AstraZeneca's Lynparza (olaparib).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.